Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell therapy in scleroderma.

Yolanda Braun-Moscovici1, Daniel E Furst

  • 1Rheumatology Division, UCLA Medical School, Los Angeles, California 90095, USA.

Current Opinion in Rheumatology
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026
Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026
Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Stem cell therapy shows promise for treating severe scleroderma, a serious autoimmune disease with limited options. Ongoing clinical trials are evaluating its effectiveness and safety in patients with poor prognostic features.

Area of Science:

  • Immunology
  • Hematology
  • Rheumatology

Background:

  • Scleroderma presents a high mortality rate, particularly in early diffuse stages with poor prognostic indicators like high skin scores and internal organ involvement.
  • Current therapeutic options for scleroderma are limited, highlighting the need for novel treatment strategies.
  • The autoimmune pathogenesis of scleroderma, especially in its early phases, suggests potential benefits from immunomodulatory approaches like stem cell therapy.

Purpose of the Study:

  • To review the rationale, regimens, and recent pilot study data for high-dose immunosuppressive therapy and stem cell transplantation in scleroderma.
  • To assess the potential of stem cell therapy as a viable treatment option for scleroderma patients.
  • To inform the design and implementation of future controlled clinical studies.

Related Experiment Videos

Main Methods:

  • Review of existing literature on high-dose immunosuppressive therapy and stem cell transplantation in scleroderma.
  • Analysis of data from pilot studies investigating stem cell therapy for scleroderma.
  • Identification of patient selection criteria and appropriate therapeutic regimens.

Main Results:

  • Pilot studies have yielded encouraging data regarding the efficacy of stem cell therapy in scleroderma.
  • The review supports the feasibility of stem cell transplantation, particularly for patients with poor prognostic features.
  • Established criteria for patient selection and therapy regimens are crucial for successful outcomes.

Conclusions:

  • Stem cell therapy represents a promising therapeutic avenue for scleroderma, given its autoimmune basis and the limitations of current treatments.
  • Encouraging pilot data warrant further investigation through controlled studies.
  • Ongoing and planned clinical trials in Europe and the United States are essential to validate the effectiveness and safety of stem cell transplantation for scleroderma.